Biotricity FY2025 EPS Forecast Decreased by HC Wainwright

Biotricity, Inc. (NASDAQ:BTCY) – Stock analysts at HC Wainwright reduced their FY2025 EPS estimates for Biotricity in a research note issued on Monday, November 18th. HC Wainwright analyst K. Dede now forecasts that the company will earn ($0.67) per share for the year, down from their prior forecast of ($0.43). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Biotricity’s current full-year earnings is ($0.43) per share.

Biotricity (NASDAQ:BTCY) last posted its quarterly earnings results on Monday, August 19th. The company reported ($0.49) earnings per share (EPS) for the quarter. The business had revenue of $3.20 million during the quarter.

Biotricity Stock Down 14.9 %

NASDAQ BTCY opened at $0.31 on Wednesday. The stock has a market capitalization of $7.12 million, a PE ratio of -0.27 and a beta of 1.22. The firm has a 50 day moving average of $0.34 and a two-hundred day moving average of $0.64. Biotricity has a 52 week low of $0.19 and a 52 week high of $1.67.

Institutional Trading of Biotricity

A hedge fund recently bought a new stake in Biotricity stock. AE Wealth Management LLC purchased a new stake in Biotricity, Inc. (NASDAQ:BTCY) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 97,751 shares of the company’s stock, valued at approximately $88,000. AE Wealth Management LLC owned about 0.45% of Biotricity at the end of the most recent reporting period. 3.89% of the stock is owned by institutional investors.

Biotricity Company Profile

Biotricity, Inc, a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses.